|
|
|
|
|
|
|
|
|
|
Blogger's Note: also of interest to those with dual (endometrial/ovarian)malignancies
Abstract
Highlights
- •
- We reviewed the clinical data of second-line platinum-based chemotherapy in patients with recurrent endometrial cancer.
- •
- Platinum-free interval was a predictor of response and survival in patients with recurrent endometrial cancer, who received second-line platinum-based chemotherapy.
- •
- The concept of “platinum sensitivity” is applicable to recurrent endometrial cancer.
Objective
The
concept of “platinum sensitivity” has been widely applied in the
management of recurrent ovarian cancer. This study aimed to evaluate the
applicability of this concept to recurrent endometrial cancer.
Patients and methods
In
this multicenter retrospective cohort study, the clinical data of
patients with recurrent endometrial cancer, who had a history of
receiving first-line platinum-based chemotherapy and who received
second-line platinum-based chemotherapy at the time of recurrence
between January 2005 and December 2009 were reviewed.
Results
A
total of 262 patients from 30 centers with initial FIGO stage
classifications of I (29), II (23), III (122), and IV (88) were
enrolled. In total, 153 endometrioid adenocarcinomas, 34 serous
adenocarcinomas, 17 clear cell adenocarcinomas, 36 carcinosarcomas, and
22 “other” tumors were documented. The response rates for patients with
platinum-free intervals of < 6 months, 6–11 months, 12–23 months, and
≥ 24 months were 25%, 38%, 61%, and 65%, respectively. The median
progression-free survival after second-line platinum-based chemotherapy
for patients with platinum-free intervals of < 12 months and
≥ 12 months was 4.4 (95% confidence interval (CI) = 3.7–5.8) months and
10.3 (95% CI = 8.2–12.6) months, respectively (log-rank P
< 0.0001), and the median overall survival was 13.8 (95%
CI = 10.6–18.1) months and 40.9 (95% CI = 25.3–54.2) months,
respectively (log-rank P < 0.0001).
Conclusion
Platinum-free
interval is a predictor of response and survival after second-line
platinum-based chemotherapy in patients with recurrent endometrial
cancer. The concept of “platinum sensitivity” could be applicable to
recurrent endometrial cancer.
Purchase $39.95
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.